This trial is a cardiovascular outcome study comparing the cagrilintide combination with Semaglutide (Ozempic) versus placebo in patients with obesity and established cardiovascular disease.

If you have had cardiovascular disease and are obese please contact us for more information: research@nightingalecardiology.com call us on (08) 7444 4219